20 results
Page of 2
  • ACCL1333

    A study designed to evaluate the safety and efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in children with newly diagnosed Acute Lympho.

    Type: Treatment

    Principal Investigator: Richard Drachtman, MD

    Trial is open for enrollment

    For inquiries, call (732) 235-8861
    • Rutgers Robert Wood Johnson Medical School
    • Robert Wood Johnson University Hospital
  • AEGIS II

    A phase 3, multi-center, double-blind, randomized, placebo-controlled, parallel-group study designed to investigate the efficacy and safety of CSL 112 (Apolipoprotein A-I: human) on reducing the risk of major adverse CV events in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including those managed with percutaneous coronary intervention (PCI) or medically managed.

    Type: Treatment

    Trial is open for enrollment

    View All Details

    • Principal Investigator:
      Sharan Mahal, MD

    For inquiries, call (908) 864-4027
    • RWJ University Hospital Somerset
  • ARRAY 797-301

    A phase 3, multinational, randomized, placebo-controlled study of ARRY-371797 in patients with symptomatic dilated cardiomyopathy due to a lamin A/C gene mutation.

    Type: Drug trial

    Principal Investigator: Saurabh Kapoor, MD

    Trial is open for enrollment

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
  • ASAP-TOO

    The purpose of this study is to establish the safety and effectiveness of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device, including the post-implant medication regimen, for subjects with non-valvular atrial fibrillation who are deemed not to be eligible for anti-coagulation therapy to reduce the risk of stroke.

    Type: Device trial

    Principal Investigator: David Dobesh, MD

    Trial is open for enrollment

    For inquiries, call (973) 736-6333
    • Saint Barnabas Medical Center
  • CIRT

    A randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with type 2 diabetes or metabolic syndrome that have had a heart attack or multiple coronary blockages.

    Type: Drug trial

    Principal Investigator: John B. Kostis, MD

    Trial is open for enrollment

    For inquiries, call (732) 235-6546
    • Rutgers Robert Wood Johnson Medical School
    • Robert Wood Johnson University Hospital
  • CLASP II TR

    A study designed to evaluate the safety and effectiveness of transcatheter tricuspid valve repair with the Edwards PASCAL Transcatheter Valve Repair System and optimal medical therapy (OMT) compared to OMT alone in patients with tricuspid regurgitation.

    Principal Investigator: Mark Russo, MD

    Type: Device

    This trial is open for enrollment

    For inquiries, call (732) 235-9215
    • Robert Wood Johnson University Hospital
    • RWJ University Hospital Somerset
  • Connect-HF

    A large-scale, pragmatic, cluster-randomized clinical trial to evaluate the effect of a customized, multi-faceted, health system-level quality improvement (QI) program compared with usual care on heart failure (HF) outcomes and HF quality-of-care metrics

    Type: Treatment

    Trial is open for enrollment

    View All Details

    • Principal Investigator:
      Sharan Mahal, MD

    For inquiries, call (908) 864-4027
    • RWJ University Hospital Somerset
  • Dapa-HF

    Evaluation of the effect of dapagilifiozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction.

    Type: Drug trial

    Principal Investigator: John B. Kostis, MD

    Trial is open for enrollment

    For inquiries, call (732) 235-6546
    • Rutgers Robert Wood Johnson Medical School
    • Robert Wood Johnson University Hospital
  • EARLY TAVR

    Evaluation of Transcatheter Aortic Valve Replacement (TAVR) compared to surveillance for patients with asymptomatic severe aortic stenosis.

    Type: Device trial

    Principal Investigator: Sergio Waxman, MD (NBIMC) or Mark Russo, MD (RWJMS/RWJUH)

    Trial is open for enrollment

    For inquiries, call (973) 926-6938 (NBIMC) or (732) 235-9215 (RWJMS/RWJUH)

    For inquiries, call (973) 926-6938
    • Newark Beth Israel Medical Center
    • Rutgers Robert Wood Johnson Medical School
    • Robert Wood Johnson University Hospital
  • Effect of GBT440 in Pediatrics With Sickle Cell Disease

    A study designed to evaluate the pharmacokinetics, safety, tolerability, and exploratory treatment effect of GBT440 in adolescents with Sickle Cell Disease.

    Type: Treatment

    Principal Investigator: Richard Drachtman, MD

    Trial is open for enrollment

    For inquiries, call (732) 235-5976
    • Rutgers Robert Wood Johnson Medical School
    • Robert Wood Johnson University Hospital
  • EVP-DEV-LTX-301

    The objective of this study is to evaluate the safety and effectiveness of the CLES in enabling evaluation of potential donor lungs not otherwise used for transplant into subjects with end stage, survival-limiting lung disease in need of lung transplantation.

    Type: Device trial

    Principal Investigator: Jesus Gomez-Abraham, MD

    Trial is open for enrollment

    For inquiries, call (973) 926-8451

    For inquiries, call (973) 926-8451
    • Newark Beth Israel Medical Center
  • GUIDE-HF

    A study designed to demonstrate the effectiveness of the CardioMEMS Heart Failure System in an expanded patient population, including heart failure patients outside of the present indication, but at risk for future heart failure (HF) events or mortality.

    Type: Device trial

    Principal Investigator: Donald Rubenstein, MD

    Trial is open for enrollment

    For inquiries, call (973) 926-8451
    • Saint Barnabas Medical Center
    • Newark Beth Israel Medical Center
Page of 2